Healthcare AI Has a Reimbursement Problem — and It's Now the Biggest Obstacle to Hospital Adoption

By Hector Herrera | June 15, 2026 | Health

Three-quarters of US hospitals are now using AI diagnostic tools that can detect tumors with 94% accuracy — but most of those hospitals can't bill for the AI read. They absorb the cost entirely, with no reimbursement pathway from Medicare, Medicaid, or private insurers. That financial reality, not the technology itself, has become the defining bottleneck slowing AI adoption across American healthcare.

Healthcare Dive's 2026 analysis identifies payment model reform — specifically the absence of Current Procedural Terminology (CPT) codes and reimbursement pathways for AI-assisted diagnosis — as the single most important factor determining whether hospital AI deployments scale or stall.

The Technology Works. The Business Model Doesn't.

The clinical performance of healthcare AI has crossed the threshold that earlier skeptics demanded. In radiology, AI algorithms are now exceeding 94% accuracy in tumor detection — a level competitive with experienced radiologists in many study conditions, and superior to them in consistency and fatigue resistance. According to Healthcare Dive, 74% of US hospitals have deployed some form of AI diagnostic tool, primarily in radiology and medical imaging.

That adoption rate looks impressive. The economics underneath it don't.

Here's the problem: In US healthcare, a hospital doesn't get paid for what it does — it gets paid for what it can bill. The billing system runs on CPT codes (Current Procedural Terminology codes), a standardized catalog of medical procedures that insurers use to determine reimbursement. Most AI-assisted diagnostic tools currently have no CPT codes, meaning:

• The hospital pays for the AI software subscription
• The hospital pays for the compute to run it
• The hospital pays for the radiologist to supervise the output
• The hospital gets reimbursed for the radiologist's read — not for the AI component at all

In some cases, using AI in the workflow may even complicate billing if the insurer questions whether a human reviewed the study. The result is that hospital CFOs see AI as a cost center rather than a revenue driver, which limits how aggressively administrators can scale deployments.

Why the Reimbursement Gap Exists

The CPT code system is managed by the American Medical Association and updated annually, but creating new codes for AI-assisted procedures is a slow, evidence-intensive process. Developers must demonstrate not just clinical efficacy but also that the AI component adds sufficient distinct value to warrant a separate billable service — a high bar in a system built around physician-delivered care.

Medicare's coverage decisions then follow CMS (Centers for Medicare & Medicaid Services) review, which can take additional years. Private insurers generally follow CMS leadership, so a negative CMS coverage decision effectively shuts off the reimbursement pathway for the entire commercial market.

The result is a structural lag: AI tools are advancing faster than the billing infrastructure that would allow hospitals to recover their costs. This isn't unique to AI — it happened with telemedicine before COVID forced CMS to temporarily expand reimbursement — but AI's breadth and speed are making the gap more acute than anything the healthcare system has previously encountered.

Japan Is Trying a Different Model

The Healthcare Dive analysis highlights IBM and Fujitsu's recently announced joint medical cloud for Japanese hospitals as an example of a publicly-funded AI deployment model worth watching.

In Japan, the government has taken a more direct role in funding AI integration into the healthcare system, allowing the costs to be socialized rather than absorbed by individual hospital balance sheets. The IBM-Fujitsu cloud provides a shared AI infrastructure that participating hospitals access through a government-backed arrangement, bypassing the per-hospital reimbursement calculation entirely.

This is structurally closer to how European single-payer systems are absorbing AI costs — through national or regional procurement rather than the procedure-by-procedure billing that dominates US healthcare. Whether the US moves toward any form of shared public AI health infrastructure is a political question, but Japan's model is drawing attention from US health system executives who see no clean path through the reimbursement maze.

What Needs to Change — and What Hospitals Can Do Now

The reimbursement pathway requires action on multiple fronts:

• CMS must create AI-specific CPT codes for demonstrably effective AI diagnostic tools — particularly in radiology, where the evidence base is strongest
• AMA must accelerate the code creation process for AI-assisted procedures that meet clinical efficacy thresholds
• Private insurers must move to cover AI-assisted reads once CMS sets coverage precedent, rather than waiting for case-by-case negotiations
• AI vendors must invest in CPT code advocacy as part of their go-to-market strategy, not as an afterthought

In the meantime, hospitals with existing AI deployments can take practical steps: document every efficiency gain, quality improvement, and error reduction that AI generates. That data is the evidence base for the reimbursement arguments that will need to be made in front of CMS — and having it ready will matter when the regulatory window opens.

What to Watch

Watch CMS's annual CPT code update cycle — the next major opportunity for AI diagnostic codes to be created is the standard AMA RUC process, with recommendations due well before the January 2027 implementation date. The American College of Radiology has been the most aggressive medical society in pushing for AI reimbursement pathways, and their advocacy with CMS will be the leading indicator of progress. Also watch whether any major insurer breaks ahead of CMS to offer direct AI reimbursement as a competitive differentiator — that would accelerate the timeline significantly.

Hector Herrera covers AI in healthcare and medicine for NexChron.

Medical disclaimer: This article is informational reporting on healthcare industry trends and does not constitute medical advice. Consult qualified healthcare professionals for medical guidance.